The RAPSN gene myasthenic syndrome congenital type 11, associated with acetylcholine receptor deficiency, is a rare genetic disorder that affects the communication between nerves and muscles, leading to muscle weakness and fatigue. This condition is caused by mutations in the RAPSN gene, which plays a crucial role in clustering and maintaining acetylcholine receptors at the neuromuscular junction. These receptors are essential for muscle contraction, and their deficiency disrupts normal muscle function.
To diagnose this specific type of congenital myasthenic syndrome, a genetic test is available at DNA Labs UAE. The test involves analyzing the patient's DNA to identify mutations in the RAPSN gene that are responsible for the condition. This precise genetic testing is crucial for confirming the diagnosis, understanding the disease's severity, and guiding treatment decisions.
The cost of the RAPSN gene myasthenic syndrome congenital type 11 genetic test at DNA Labs UAE is 4400 AED. This investment enables patients and their families to gain vital insights into the genetic basis of the muscle weakness experienced, paving the way for personalized treatment approaches and management strategies to improve quality of life.
The "SLC5A7 Gene Myasthenic Syndrome Congenital Type 20 Presynaptic Genetic Test" is a specialized diagnostic assessment designed to identify mutations in the SLC5A7 gene, which are associated with Congenital Myasthenic Syndrome Type 20 (CMS20). This condition falls under a broader category of genetic disorders known as congenital myasthenic syndromes (CMS), which are characterized by muscle weakness and fatigue due to the impaired transmission of signals between nerves and muscles. The SLC5A7 gene plays a crucial role in the presynaptic region of the neuromuscular junction, and its mutations can lead to a deficiency in the release of acetylcholine, a key neurotransmitter for muscle contraction.
This genetic test is conducted through a blood sample, where DNA is extracted and analyzed for any abnormalities or mutations in the SLC5A7 gene. It is particularly valuable for individuals exhibiting symptoms of muscle weakness, fatigue without an obvious cause, or those with a family history of CMS. Early and accurate diagnosis through this test can lead to better management and treatment options for the affected individuals.
The test is available at DNA Labs UAE, a leading facility in genetic testing and analysis. The cost of the test is 4400 AED, which reflects the comprehensive nature of the analysis, including the use of advanced genetic sequencing technologies and the expertise required to interpret the results accurately. This test is a critical step towards personalized medicine for patients with CMS20, offering them a chance for improved quality of life through targeted therapies and interventions based on their genetic makeup.
The CHRND Gene Myasthenic Syndrome Congenital Type 3A Slow Channel Genetic Test is a specialized diagnostic assessment available at DNA Labs UAE. Priced at 4400 AED, this test specifically targets the CHRND gene to identify mutations associated with Congenital Myasthenic Syndrome Type 3A (CMS Type 3A), a rare hereditary neuromuscular disorder characterized by muscle weakness and fatigue. The condition is attributed to a slow-channel congenital myasthenic syndrome, which results from the prolonged opening of the acetylcholine receptor channels at the neuromuscular junction, leading to a disruption in muscle contraction and strength.
This genetic test is critical for accurate diagnosis and management of the condition, providing essential information for personalized treatment plans. It involves collecting a DNA sample from the patient, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for specific mutations in the CHRND gene. The results can have significant implications for treatment strategies, including the use of cholinesterase inhibitors or other targeted therapies that can improve muscle function and quality of life for affected individuals.
By offering this test, DNA Labs UAE plays a vital role in the early detection and management of Congenital Myasthenic Syndrome Type 3A, enabling patients and their families to understand their condition better and to explore the most effective treatment options available.
The CHRND Gene Myasthenic Syndrome Congenital Type 3B Fast-Channel Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE, designed to identify mutations in the CHRND gene. This gene plays a crucial role in the proper functioning of the neuromuscular junction, which is essential for muscle contractions. Mutations in the CHRND gene can lead to Congenital Myasthenic Syndrome Type 3B, a rare disorder characterized by muscle weakness and fatigue, with symptoms often appearing at birth or early childhood.
This specific test targets the fast-channel form of the condition, where the communication between nerves and muscles is impaired due to alterations in the acetylcholine receptor at the neuromuscular junction. By analyzing the genetic makeup of an individual, this test can confirm the presence of CHRND gene mutations, providing essential information for accurate diagnosis, management, and treatment planning.
The cost of the CHRND Gene Myasthenic Syndrome Congenital Type 3B Fast-Channel Genetic Test at DNA Labs UAE is 4400 AED. This investment includes the comprehensive analysis necessary to detect the genetic underpinnings of this condition, offering patients and their families critical insights into their health and guiding healthcare professionals in delivering personalized care strategies.
The CHRND gene myasthenic syndrome congenital type 3C, associated with acetylcholine receptor deficiency, is a rare genetic disorder that affects the communication between nerves and muscles, leading to muscle weakness and fatigue. This condition is caused by mutations in the CHRND gene, which plays a crucial role in the proper functioning of the acetylcholine receptors at the neuromuscular junction. These receptors are essential for muscle contraction, and their deficiency disrupts normal muscle function.
To diagnose this condition, a specific genetic test is available at DNA Labs UAE. This test involves analyzing the patient's DNA to identify mutations in the CHRND gene that are responsible for the syndrome. The test is crucial for confirming the diagnosis, understanding the disease's severity, and guiding treatment decisions.
The cost of the CHRND gene myasthenic syndrome congenital type 3C genetic test at DNA Labs UAE is 4400 AED. This investment allows for a comprehensive analysis, providing patients and their families with essential information for managing the condition effectively. Early diagnosis through this genetic testing can significantly improve the quality of life for those affected by facilitating timely and appropriate interventions.
The DRD2 gene myoclonic dystonia DRD2 related genetic test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the DRD2 gene, which are linked to the development of myoclonic dystonia. Myoclonic dystonia is a neurological movement disorder characterized by quick, involuntary muscle contractions (myoclonus) and prolonged muscle contractions (dystonia) that result in twisting and repetitive movements or abnormal postures. The DRD2 gene plays a crucial role in the dopamine signaling pathway, which is essential for controlling movement, emotional response, and pain processing in the brain. Mutations in the DRD2 gene can disrupt this pathway, leading to the symptoms associated with myoclonic dystonia.
The test is conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services. It involves collecting a DNA sample from the patient, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect any genetic alterations in the DRD2 gene that might be responsible for the condition. This test is crucial for individuals experiencing symptoms of myoclonic dystonia or those with a family history of the disorder, as it can provide a definitive diagnosis and guide treatment options.
The cost of the DRD2 gene myoclonic dystonia DRD2 related genetic test at DNA Labs UAE is 4400 AED. Although the price may seem high, the test offers invaluable insights into the genetic basis of the disorder, enabling targeted interventions and potentially improving the quality of life for those affected by myoclonic dystonia.
The EPM2A gene myoclonic epilepsy of Lafora genetic test is a specialized diagnostic procedure designed to identify mutations in the EPM2A gene, which are known to cause Lafora disease. Lafora disease is a rare, autosomal recessive disorder characterized by the presence of Lafora bodies (abnormal glycogen inclusions) within cells, leading to progressive myoclonus epilepsy. This condition typically manifests in late childhood or adolescence, resulting in seizures, muscle spasms, and neurological decline.
The test is crucial for early diagnosis and management of the condition, enabling healthcare providers to tailor treatment plans that can potentially slow the disease's progression and improve the quality of life for affected individuals. It involves collecting a DNA sample, usually through a blood draw, which is then analyzed in the laboratory for specific mutations in the EPM2A gene.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test for EPM2A gene myoclonic epilepsy of Lafora is priced at 4400 AED. The laboratory is equipped with advanced technology and staffed by experts in genetic diagnostics, ensuring high accuracy and reliability of the test results. Opting for this test at DNA Labs UAE provides patients and their families with crucial information for managing Lafora disease, supported by the lab's commitment to excellence in genetic analysis and customer care.
The NHLRC1 Gene Myoclonic Epilepsy of Lafora Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in the NHLRC1 gene, which are linked to Lafora disease, a rare and severe form of myoclonic epilepsy. Lafora disease is characterized by the accumulation of Lafora bodies within cells, leading to progressive neurological deterioration that typically begins in late childhood or adolescence. Symptoms include myoclonus, seizures, and cognitive decline, among others.
The test, priced at 4400 AED, involves analyzing the patient's DNA to identify specific genetic alterations in the NHLRC1 gene that are known to cause Lafora disease. This genetic insight is crucial for confirming a diagnosis, understanding the disease's progression, and potentially guiding treatment decisions. The procedure is carried out in the state-of-the-art facilities of DNA Labs UAE, ensuring high-quality, reliable results. Identifying carriers of the mutation can also provide valuable information for family planning purposes, as Lafora disease is inherited in an autosomal recessive pattern.
The "NOL3 Gene Myoclonus Familial Cortical Genetic Test" is a specialized diagnostic tool designed to identify mutations in the NOL3 gene, which have been linked to familial cortical myoclonus. Familial cortical myoclonus is a rare neurological disorder characterized by quick, involuntary muscle jerks originating from the cerebral cortex, often inherited in an autosomal dominant pattern. Mutations in the NOL3 gene disrupt normal brain function, leading to these characteristic symptoms.
This genetic test involves analyzing the patient's DNA to look for specific mutations in the NOL3 gene that are known to cause the condition. Identifying these mutations can confirm a diagnosis of familial cortical myoclonus, which is crucial for managing the condition effectively. Early diagnosis can help in tailoring treatment plans that may include medications, lifestyle adjustments, and monitoring for potential complications.
The test is available at DNA Labs UAE, a leading facility in genetic testing and diagnostics. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the expertise required to interpret the results accurately. DNA Labs UAE provides comprehensive support throughout the testing process, from sample collection to result interpretation, ensuring that patients and their families receive the information and guidance they need to manage the condition effectively.
The LPIN1 gene plays a crucial role in lipid metabolism within the body. Mutations in this gene can lead to a condition known as acute recurrent myoglobinuria, which is characterized by repeated episodes of muscle pain, weakness, and the release of myoglobin into the urine. This condition can lead to serious complications, including kidney damage, if not diagnosed and managed properly.
DNA Labs UAE offers a genetic test specifically designed to identify mutations in the LPIN1 gene that are associated with acute recurrent myoglobinuria. This test is crucial for individuals who have experienced symptoms of the condition or have a family history of similar symptoms. Early detection through this genetic test can facilitate timely management and intervention strategies to prevent complications.
The cost of the LPIN1 Gene Myoglobinuria Acute Recurrent Genetic Test at DNA Labs UAE is 4400 AED. This test is a valuable tool for healthcare providers in diagnosing this rare but potentially severe condition, allowing for personalized treatment plans based on the genetic makeup of the individual.
